Specify a stock or a cryptocurrency in the search bar to get a summary
Catalyst Pharmaceuticals Inc
CPRXCatalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida. Address: 355 Alhambra Circle, Coral Gables, FL, United States, 33134
Analytics
WallStreet Target Price
30.14 USDP/E ratio
36.1607Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CPRX
Dividend Analytics CPRX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CPRX
Stock Valuation CPRX
Financials CPRX
Results | 2019 | Dynamics |